Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis

Annals of Internal Medicine

Volumn 130, Issue 10, 1999, Pages 789-799

  Gould, Michael K ^a   Dembitzer, Anne D ^a   Sanders, Gillian D ^b   Garber, Alan M ^b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; ARTICLE; BLEEDING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; FEMALE; HEALTH CARE COST; HEPARINIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; ORAL DRUG ADMINISTRATION; PHLEBITIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

EID: 0032925807     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-130-10-199905180-00002     Document Type: Article

References (41)

1. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992;326:975-82.
2. Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med. 1996;334:682-7.
3. Levine M, Gent M, Hirsh J, Leclerc J, Andersen D, Weitz J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677-81.
4. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. N Engl J Med. 1997;337:657-62.
5. Menzin J, Colditz GA, Regan MM, Richner RE, Oster G. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med. 1995;155: 757-64.
6. Anderson DR, O'Brien BJ, Levine MN, Roberts R, Wells PS, Hirsh J. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip replacement. Ann Intern Med. 1993;119:1105-12.
7. Lindmarker P, Holmstrom M. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Thrombosis Dalteparin Trial Group. J Intern Med. 1996;240:395-401.
8. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1172-7.
9. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276:1253-8.
10. Drummond MF, Richardson WS, O'Brien BJ, Levine M, Heyland D. Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA. 1997;277:1552-7.
11. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford Univ Pr; 1996.
12. Russell LB, Siegel JE, Daniels N, Gold MR, Luce BR, Mandelblatt JS. Cost-effectiveness analysis as a guide to resource allocation in health: roles and limitations. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds, Cost-Effectiveness in Health and Medicine. New York: Oxford Univ Pr; 1996;3-24.
13. Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sie P, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med. 1993;153:1541-6.
14. Lindmarker P, Holmstrom M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost. 1994;72:186-90.
15. Fiessinger J, Lopez-Fernandez M, Gatterer E, Granqvist S, Kher A, Olsson CG, et al. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost. 1996;76:195-9.
16. Luomanmaki K, Granqvist S, Hallert C, Jauro I, Ketola K, Kim HC, et al. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. J Intern Med. 1996;240:85-92.
17. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med. 1999;130:800-9.
18. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1-7.
19. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study. Thromb Haemost. 1991;65:251-6.
20. Prandoni P, Lensing AW, Buller HR, Carta M, Cogo A, Vigo M, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet. 1992;339:441-5.
21. Lopaciuk S, Meissner AJ, Filipecki S, Zawilska K, Sowier J, Ciesielski L, et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thromb Haemost. 1992;68:14-8.
22. Philbrick JT, Becker DM. Calf deep venous thrombosis. A wolf in sheep's clothing? Arch Intern Med. 1988;148:2131-8.
23. Passman MA, Moneta GL, Taylor LM Jr, Edwards JM, Yeager RA, McConnell DB, et al. Pulmonary embolism is associated with the combination of isolated calf vein thrombosis and respiratory symptoms. J Vasc Surg. 1997;25:39-45.
24. Leizorovicz A. Efficacy and safety of low molecular weight heparin (enoxaparin) and unfractionated heparin in proximal deep vein thrombosis [Abstract]. Thromb Haemost. 1997;Suppl:290.
25. Bergqvist D, Jendteg S, Johansen L, Persson U, Odegaard K. Cost of long-term complications of deep venous thrombosis of the lower extremities: an analysis of a defined patient population in Sweden. Ann Intern Med. 1997;126:454-7.
26. National Center for Health Statistics. Abridged U.S. Life Tables. Hyattsville, MD: U.S. Department of Health and Human Services; 1994. Available at http://www.cdc.gov/nchswww.
27. Fryback D, Dasbach E, Klein R, Klein BE, Dorn N, Peterson K, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13:89-102.
28. Lenert LA, Soetikno RM. Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. J Am Med Inform Assoc. 1997;4:49-56.
29. HCIA, Inc. Length of Stay by Diagnosis, United States. Baltimore: HCIA; 1997.
30. Torrance G. Measurement of health state utilities for economic appraisal: a review. Journal of Health Economics. 1986;5:1-30.
31. Froberg D, Kane R. Methodology for measuring health-state preferences - II: Scaling methods. J Clin Epidemiol. 1989;42:459-71.
32. Health Care Financing Administration. Medicare Provider Analysis and Review. Hyattsville, MD: U.S. Department of Health and Human Services; 1995. Available http://www.hcfa.gov/stats/stats.htm.
33. Physicians' Current Procedural Terminology. Chicago: American Medical Assoc; 1996.
34. Drug Topics Red Book. Montvale, NJ: Medical Economics; 1997.
35. Health Care Financing Administration. 1997 adjusted average per capita cost (AAPCC) for Tax Equity and Fiscal Responsibility Act of 1982 (TERFA) risk contractors - information. Hyattsville, MD: U.S. Department of Health and Human Services; 1997. Available at http://www.hcfa.gov/stats/cover97.txt.
36. Bureau of Labor Statistics. National Current Employment Statistics Washington, DC: U.S. Department of Labor; 1997. Available at http://stats.bls.gov/ ceshome.htm.
37. Bureau of Labor Statistics. Consumer Expenditure Survey. Washington, DC: U.S. Department of Labor; 1995. Available at http://stats.bls.gov/csxhome .htm.
38. Siegel JE, Weinstein MC, Torrance GW. Reporting cost-effectiveness studies and results. In Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford Univ Pr; 1996:276-303.
39. Hull R, Raskob G, Rosenbloom D, Pineo GF, Lemer RG, Gafni A, et al. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. Arch Intern Med. 1997;157:289-94.
40. Luce BR, Manning WG, Siegel JE, Liscomb J. Estimating costs in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford Univ Pr; 1996: 176-213.
41. Weitz J. Low-molecular-weight heparins. N Engl J Med. 1997;337:688-98.